ASN Kidney Week at a glance
ASN Kidney Week 2026 highlights emerging developments in kidney disease treatment, from IgA nephropathy (IgAN) and complement inhibition to immune-targeted therapies, precision nephrology and cardio-kidney-metabolic (CKM) protection.
The conference also brings attention to competitive developments in emerging kidney therapies, alongside artificial intelligence and digital health applications for kidney-risk prediction, clinical decision support and remote monitoring.
📅 Build your schedule around the sessions that matter most.
📥 Download the ASN 2026_Preview_by_LucidQuest
ASN Kidney Week 2026: Key Developments in Kidney Disease Treatment
IgA Nephropathy Treatment Sequencing
APRIL/BAFF inhibition, complement blockade and endothelin targeting will compete on proteinuria, eGFR, durability, safety and treatment burden.
Complement Inhibitors in Kidney Disease
Iptacopan, pegcetacoplan, ravulizumab and crovalimab will highlight expanding opportunities across IgAN, C3G, IC-MPGN and aHUS.
Lupus Nephritis Treatment: CAR T and Immune Reset
FT819 CAR T, budoprutug and anti-CD38 strategies will test deeper immune targeting in lupus nephritis and membranous nephropathy.
Precision Nephrology and APOL1-Targeted Treatment
MZE829 HORIZON data could strengthen the case for APOL1-directed treatment and genetically defined kidney disease pathways.
Chronic Kidney Disease Treatment and CKM Protection
Finerenone, SGLT2 inhibitors and incretin-based therapies will raise new questions around treatment layering and patient selection.
New Kidney Therapies and Competitive Developments
Vera Therapeutics and Otsuka Pharmaceutical
Atacicept ORIGIN 3 and sibeprenlimab VISIONARY data will inform APRIL-targeted differentiation in IgAN.
Novartis and Alexion Pharmaceuticals
IgAN heterogeneity and complement biology will feature in discussions of mechanism-based treatment selection.
Biogen and Genentech
Plasma-cell biology and intensive B-cell-directed approaches will inform immune-mediated kidney disease positioning.
Emerging Kidney Therapies: ARGX-121, PYC-003 and GE8820
ARGX-121, PYC-003 and GE8820 will add new mechanisms to the early-stage development landscape.
Artificial Intelligence and Machine Learning at ASN Kidney Week 2026
AI-Based Risk Prediction in Nephrology
Multicenter models and deep-learning pathology will explore earlier kidney-risk identification and more precise clinical assessment.
Digital Kidney Care and Remote Monitoring
Treat CKD, SmartNTx and CloudCath will test decision support, telemedicine and remote monitoring across kidney care.
What to Watch After ASN Kidney Week 2026
- Whether IgAN datasets establish clearer treatment sequencing.
- Whether APOL1 inhibition and CAR T demonstrate clinically meaningful renal responses.
- Whether AI prediction translates into actionable intervention and routine care.
Download LucidQuest’s ASN Kidney Week 2026 Preview Report
Download our ASN Kidney Week 2026 preview report for deeper analysis of emerging kidney therapies, IgAN treatment sequencing, complement inhibition, precision nephrology, competitor positioning and AI applications in kidney care.
📅 Build your schedule around the topics that matter most.
📥 Download the ASN 2026_Preview_by_LucidQuest
Contact us for end-to-end conference coverage.
